13.05.2014
Vita 34 AG DE000A0BL849
DGAP-News: Vita 34 AG: Close Brothers Seydler Starts Coverage of Vita 34 Stock
DGAP-News: Vita 34 AG / Key word(s): Miscellaneous
Vita 34 AG: Close Brothers Seydler Starts Coverage of Vita 34 Stock
13.05.2014 / 10:48
---------------------------------------------------------------------
Vita 34 AG: Close Brothers Seydler Starts Coverage of Vita 34 Stock
Leipzig, 13 May 2014 - Vita 34 AG (WKN A0BL84), a pioneer in the storage of
stem cells from umbilical cord blood and tissue, as well as a specialist in
cryo-preservation, announces that the analysts at Close Brothers Seydler
Research AG (CBS Research) have started coverage of the Vita 34 stock.
In their initial research report, published today, the analysts have
expressed a buy recommendation with a target price of EUR 7.10.
The analysts identified advances in the development of therapies using stem
cells from umbilical cord blood and tissue, as well as a growing number of
stem cell transplantation, as major drivers of growth. The variety of
applications for autologous stem cells provides a great deal of potential
to the field of regenerative medicine, and should contribute to increasing
storage rates. In addition, the analysts see a positive effect on revenue
growth from the strategic direction of expanding international activities
via partners. Additional potential is offered by the expansion of the
product range. For example, the introduction of the new product
"VitaPlusNabelschnur" [VitaPlusCord] should have a significant effect on
the group revenues and profits of Vita 34. In all, Vita 34 will use its
corporate strengths, experience and innovative power to expand its already
strong market position.
Dr. André Gerth, Chairman of the Management Board of Vita 34 AG, commented
on the start of coverage: "We are pleased to again be able to provide our
investors with an important source of information in the form of the
current stock research report from CBS Research, in order to arrive at the
most objective assessment of our growth potential possible. It is,
moreover, a component of our significantly enhanced investor relations
strategy aimed towards increasing the transparency of our company, and
convincing additional private and institutional investors of the future
opportunities available to Vita 34."
The complete research report is available for download as of today on the
website at www.vita34group.de in the "Investor Relations" section.
Company Profile
Vita 34 was founded in 1997 as the first private umbilical cord blood bank
in Europe and, as a complete provider, offers collection logistics,
preparation and storage of umbilical cord blood. The basis for its
successful work is an outstanding position in the technological segment of
cryo-preservation. Here, cells and tissues are preserved alive at
temperatures around minus 190 degrees Celsius, and can be used if needed in
the context of medical treatment. Parents of more than 104,000 children are
already taking advantage of this offering and have provided for their
children with a stem cell deposit at Vita 34. To date, 26 therapeutic
applications have been performed with stem cell preparations stored at Vita
34.
End of Corporate News
---------------------------------------------------------------------
13.05.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: [email protected]
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
268056 13.05.2014
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Vita 34 AG ISIN: DE000A0BL849 können Sie bei EQS abrufen
Biotechnologie , A0BL84 , V3V , XETR:V3V